Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

Delayed Quote. Delayed  - 02/12 04:00:00 pm
379.01 USD   +3.21%
02/09DJU.S. HOT STOCKS : Hot Stocks to Watch
02/09DJRegeneron Reports Slowing Sales Growth for Key Eye Drug
02/09 REGENERON PHARM : misses Street 4Q forecasts
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/08/2016 02/09/2016 02/10/2016 02/11/2016 02/12/2016 Date
390.53(c) 365.97(c) 367.48(c) 367.24(c) 379.01(c) Last
1 225 635 2 112 333 1 232 404 941 817 723 374 Volume
-1.53% -6.29% +0.41% -0.07% +3.20% Change
More quotes
Financials ($)
Sales 2016 5 068 M
EBIT 2016 1 822 M
Net income 2016 900 M
Finance 2016 1 796 M
Yield 2016 -
Sales 2017 5 973 M
EBIT 2017 2 391 M
Net income 2017 1 340 M
Finance 2017 3 528 M
Yield 2017 -
P/E ratio 2016 52,72
P/E ratio 2017 36,04
EV / Sales 2016 7,48x
EV / Sales 2017 6,06x
Capitalization 39 716 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
02/11 REGENERON PHARMACEUTICALS : Assigned Patent
02/09DJU.S. HOT STOCKS : Hot Stocks to Watch
02/09DJRegeneron Reports Slowing Sales Growth for Key Eye Drug
02/09 REGENERON PHARMACEUTICALS : Results of Operations and Financial Condition, Finan..
02/09 REGENERON PHARMACEUTICALS : misses Street 4Q forecasts
02/09 REGENERON PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2015 Financial ..
02/08 UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's
02/02 REGENERON PHARMACEUTICALS : Amendments to Articles of Inc. or Bylaws; Change in ..
More news
Sector news : Bio Therapeutic Drugs
02/13 LONZA : Pease Lonza may add up to 400 jobs Firm requests city cut building permi..
02/12 AMGEN : Mystery cannabis 'consortium' reportedly interested in Longmont's Amgen ..
02/12 AMGEN : Kyprolis launches in the UK for relapsed multiple myeloma
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
02/12 Healthcare ratings roundup
02/11 Amgen Valuation Now Excludes Potential Repatha Revenue
02/11 The Touchstone Sands Capital Institutional Growth Fund Is Feeling The Pain
02/10 REGENERON DISAPPOINTS, THE STOCK SEL : Analysis Of Its Growth Potential
02/09 Regeneron Pharmaceuticals' (REGN) CEO Leonard Schleifer on Q4 2015 Results - ..


Comments 
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions